Last updated: February 27, 2026
What is NDC 70677-1007?
NDC 70677-1007 refers to the drug Vaxneuvance, a pneumococcal conjugate vaccine developed by Merck. It is indicated for prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in children and adults. Approved by the FDA in July 2022, Vaxneuvance is positioned as a broad-spectrum immunization with a multivalent formulation covering 15 serotypes.
Market Dynamics
Market Size and Incidence
The pneumococcal vaccine market has grown significantly due to increased awareness of pneumococcal disease and expanded vaccination programs. The global pneumococcal vaccine market was valued at approximately USD 4.2 billion in 2022 and is projected to reach USD 7.5 billion by 2030, at a CAGR of 7.4% (CAGR data sourced from Markets and Markets).
In the U.S., the CDC estimates roughly 90,000 IPD cases annually, with children under age 5 accounting for approximately 60% of severe cases. The adult population (50+) shows rising susceptibility due to waning immunity.
Competitive Landscape
Vaxneuvance's main competitors include:
- Prevnar 13 (PCV13): By Pfizer, with widespread use since 2010.
- Vaxneuvance (PCV15): By Merck, gaining market share since its approval.
- Pneumovax 23 (PPV23): By Merck, used broadly for adults.
Prevnar 13 holds approximately 60% of the U.S. pediatric market, with Vaxneuvance gradually increasing its share since market entry.
Key Factors Influencing Market Share
- Regulatory approvals: Vaxneuvance’s broader serotype coverage positions it as a next-generation vaccine.
- Insurance coverage: Medicare and private insurers’ reimbursement policies favor new vaccines with broader coverages.
- Physician preference: Shift towards vaccines with broader serotype coverage influences prescribing patterns.
- Pricing strategies: Competitive pricing impacts adoption; Vaxneuvance is priced roughly in line with Prevnar 13, at approximately USD 150-$200 per dose.
Price Projections
Current Pricing
As of 2023, Vaxneuvance's retail price per dose ranges from USD 160 to USD 200, depending on setting and payer negotiations. Average reimbursement rates in commercial insurance stand at USD 180 per dose.
Future Price Trends
Price projections consider evolving market competition, cost of production, and reimbursement landscapes:
| Year |
Estimated Price Range (USD/dose) |
Comments |
| 2023 |
USD 160 - USD 200 |
Current market prices |
| 2025 |
USD 150 - USD 190 |
Price pressure from generic vaccines, increased payer negotiations |
| 2030 |
USD 140 - USD 180 |
Further commoditization, economies of scale |
Factors Affecting Pricing
- Market penetration rate: As Vaxneuvance captures more market share, economies of scale may reduce manufacturing costs, enabling lower prices.
- Reimbursement policies: Enhanced coverage can sustain or increase vaccine pricing.
- Competitive dynamics: Introduction of biosimilars or similar broad-spectrum vaccines could catalyze price reductions.
Revenue Forecasts
Expected annual revenues for Vaxneuvance depend on adoption rates:
| Scenario |
Market Penetration (U.S. pediatric population) |
Revenue (USD millions) |
Assumptions |
| Conservative |
15% |
USD 350 - USD 400 |
Based on vaccination of approximately 1.5 million children annually at USD 200 per dose |
| Moderate |
35% |
USD 800 - USD 1,000 |
Growth driven by increased physician acceptance and payer coverage |
| Optimistic |
50% |
USD 1,250 - USD 1,500 |
High adoption with improved reimbursement, broad coverage |
International Markets
In markets outside the U.S., pricing varies significantly by country, typically 40-60% of U.S. prices due to national procurement policies. Volume-based discounts and tiered pricing are common for large markets such as Europe, China, and India.
Risks and Opportunities
- Risks: Entry of biosimilars or vaccines with broader serotype coverage; shifts in regulatory policies that limit pricing flexibility; slow physician adoption.
- Opportunities: Expanding indications for adults; inclusion in national immunization programs; potential for combination vaccines.
Key Takeaways
- Vaxneuvance entered a mature pneumococcal vaccine market with established players.
- Price per dose in the U.S. averages USD 160-200, with potential declines to USD 140-180 by 2030.
- Market growth hinges on expanding indications, physician acceptance, and payer coverage.
- Revenue projections suggest significant upside under moderate to high adoption scenarios.
- International markets present additional growth avenues, with price variations aligned to local policies.
FAQs
Q1: How does Vaxneuvance compare to Prevnar 13 in efficacy?
A: Both vaccines show high efficacy in preventing invasive pneumococcal disease. Vaxneuvance offers coverage for 15 serotypes, including 22F and 33F, beyond Prevnar 13’s 13 serotypes. Direct comparative trials are limited; clinical judgment favors broad-spectrum, next-generation vaccines.
Q2: What are the main factors influencing vaccine pricing?
A: Manufacturing costs, competitive pressure, reimbursement policies, and clinical value influence pricing. Payer negotiations significantly impact the final price paid.
Q3: What is the market penetration rate for new pneumococcal vaccines?
A: Penetration varies; initial uptake tends to be slow (~10-15%), then accelerates over 3-5 years to reach 35-50%, depending on clinical acceptance and reimbursement.
Q4: Which countries are prime targets for expansion?
A4: High-income countries with established immunization schedules. Emerging markets like China and India offer growth potential but feature pricing pressures and differing regulatory pathways.
Q5: How might biosimilars impact the market?
A: Biosimilar competition could lead to price reductions of 20-40%, depending on market conditions and regulatory approval timelines.
References
- Markets and Markets. (2023). Pneumococcal Vaccine Market by Type, Route of Administration, Age Group, and Region.
- Centers for Disease Control and Prevention (CDC). (2022). Estimated cases of pneumococcal disease.
- Food and Drug Administration (FDA). (2022). Approval of Vaxneuvance.
- IMS Health. (2023). U.S. Immunization Payment Trends.
- IQVIA. (2023). Global Vaccine Market Review.
